In 2007, the United States Congress passed the Food and Drug Administration (FDA) Amendment . 1 The American Recovery and Reinvestment Act of 2009 committed $1.1 billion to comparative effectiveness research, to enable and strategies to prevent, diagnose, . 2 Both developments rely on expanded secondary use of observational healthcare data and have thrust the field of epidemiology into the national spotlight. In particular, these efforts require a significant evolution in the use of these data from the customized design of an individual study of a particular product-outcome association to a broader effort that effectively uses these data for active monitoring of any medical product and any health outcome of interest across a network of disparate databases. The envisioned systems would go beyond the retrospective evaluation of hypothesized effects to proactively explore the data to generate and refine hypotheses of potential issues and benefits that warrant further scrutiny. Little research currently exists to inform the development of such systems.
Focusing just on active drug safety surveillance, open questions include:
-Which statistical and epidemiological methods work best for different types of drugs and outcomes?
-What is the optimal way to combine information from disparate databases?
-What thresholds should active surveillance systems use to identify risks?
-What processes should exist to handle newly identified risks?
-How often will active surveillance system yield false positives and false negatives?
Main Text
The last question is key and no answer to it currently exists. In fact, the absence of established operating characteristics bedevils all of pharmacoepidemiology. Typical studies in observational databases attempt to control for bias by careful control for confounders, restrictions to certain patient subgroups, etc. While these issues have received scrutiny through academic discourse and isolated anecdotes in the literature, no systematic studies exist that elucidate how these issues manifest themselves in real-world data. Consequently, no assurance can be provided that estimated relative risks, odds ratios, etc., that these studies produce are anywhere near the corresponding true values or that standard 95% intervals actually contain the truth 95% of the time.
The practical complexities and intrinsic biases in real-world data suggest that answers to these questions are unlikely to arise from theoretical research and instead must derive from extensive OMOP studies the operating characteristics of methods that attempt to discern true drug-outcome associations from background noise. The basic approach thus far has comprised three bodies of work:
1. Establishing a data network, comprising the types of data anticipated for use in active surveillance and comparative effectiveness research, both administrative claims and electronic health records covering different populations, and converted to a common data model format. While early results from OMOP and from these various efforts demonstrate the promise of systematic observational analyses, they highlight significant methodological challenges that are faced when attempting to produce unbiased effect estimates in observational healthcare databases. The results also suggest much work is needed to improve the performance of existing epidemiologic methods, to maximize the likelihood of observing true effects while reducing the risk of false positive findings. Specific areas of opportunity include: enhancing strategies to identify and mitigate sources of bias, improving the extraction of clinical elements from the underlying data, developing solutions for refined outcome definitions, establishing strategies to integrate observational results across disparate data sources, and designing a broader framework for how observational analyses can contribute to a causality assessment.
The empirical findings to date appear to be consistent with prior concerns about the accuracy of epidemiologic investigations 7 , including the suggestion that only large effects be considered as credible from observational analyses 8 and the occurrence of inconsistencies in different published analyses of the same drug safety concern 9, 10 . Until observational data and analytic methods improve to the point that operating characteristics are consistent with the a credibility gap will continue to exist for epidemiologists working in this area.
Observational studies should serve as a primary, and in some circumstances, best source of evidence in evaluating the comparative safety and effectiveness of medical products 11 , but only if epidemiologic investigations have sufficient reliability to provide stakeholders with the confidence needed to inform medical decision-making. This involves demonstrating to the skeptics that epidemiology can be more than an art and treated as a science, following systematic processes that generate reproducible and fully transparent research, with well-understood operating characteristics.
In particular, clinical insights that currently underlie many design decisions in pharmacoepidemiology need to be applied consistently and subjected to rigorous evaluation.
Advancing the science of active surveillance and comparative effectiveness requires interdisciplinary collaboration between epidemiology, statistics, health services research, computer science, medical informatics, engineering, and the clinical sciences. Substantial research challenges remain but progress can translate directly into significant benefits for patients.
